ReviewCNS & neurological disorders drug targets2008
The endocannabinoid system: a new molecular target for the treatment of tobacco addiction.
Review in CNS & neurological disorders drug targets, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- THC reduces the anticipatory nucleus accumbens response to reward in subjects with a nicotine addiction.Translational psychiatry · 2013Trial
- Neurobiology of Stress-Induced Nicotine Relapse.International journal of molecular sciences · 2024Review
- Enhancing effect of nicotine on electrical field stimulation elicited contractile responses in isolated rabbit bladder straight muscle; the role of cannabinoid and vanilloid receptors.Turkish journal of medical sciences · 2022Article
- Unraveling the role of cigarette use in neural cannabis cue reactivity in heavy cannabis users.Addiction biology · 2021Article
- Gender Differences in the Association between Marijuana and Menthol Cigarette Use among African American Adult Cigarette Smokers.Substance use & misuse · 2020Article
- Chronic nicotine exposure attenuates the effects of ΔBrain and behavior · 2019Article
- Acute and chronic modulation of striatal endocannabinoid-mediated plasticity by nicotine.Addiction biology · 2019Article
- The relationship between nicotine and psychosis.Therapeutic advances in psychopharmacology · 2019Review
- Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Review
- Comorbid Cannabis and Tobacco Use in Adolescents and Adults.Current addiction reports · 2016Article
- Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg.Psychopharmacology · 2016Review
- Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives.Psychopharmacology · 2016Review
- Article
- Role of the endogenous cannabinoid system in nicotine addiction: novel insights.Frontiers in psychiatry · 2015Review
- The role of cannabinoid transmission in emotional memory formation: implications for addiction and schizophrenia.Frontiers in psychiatry · 2014Review
- Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.Pharmacology & therapeutics · 2013Review
- The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats.British journal of pharmacology · 2012Article
- Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.Neuroscience and biobehavioral reviews · 2010Review
- The future of endocannabinoid-oriented clinical research after CB1 antagonists.Psychopharmacology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Tobacco addiction is one of the leading preventable causes of mortality in the world and nicotine appears to be the main critical psychoactive component in establishing and maintaining tobacco dependence. Several lines of evidence suggest that the rewarding effects of nicotine, which underlie its abuse potential, can be modulated by manipulating the endocannabinoid system. For example, pharmacological blockade or genetic deletion of cannabinoid CB(1) receptors reduces or eliminates many behavioral and neurochemical effects of nicotine that are related to its addictive potential. This review will focus on the recently published literature about the role of the endocannabinoid system in nicotine addiction and on the endocannabinoid system as a novel molecular target for the discovery of medications for tobacco dependence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.